Sai Parenterals Acquires Remaining 25% Stake in SP Analytics

Sai Parenterals Limited announced the outcome of its Board Meeting held on November 1, 2026. The board approved the un-audited financial results for the quarter and half-year ended September 30, 2026, along with their Limited Review Reports. A significant decision was the acquisition of the remaining 25% equity shareholding in its subsidiary, SP Analytics Private Limited, making it a wholly-owned subsidiary. The company also completed the acquisition of 60% equity in Saicriti Pharma Private Limited, which now becomes a subsidiary. Additionally, a Management Committee was constituted for operational efficiency.